Immunovant Statistics
Total Valuation
Immunovant has a market cap or net worth of $8.64 billion. The enterprise value is $7.84 billion.
| Market Cap | 8.64B |
| Enterprise Value | 7.84B |
Important Dates
The last earnings date was Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Immunovant has 206.55 million shares outstanding. The number of shares has increased by 21.12% in one year.
| Current Share Class | 206.55M |
| Shares Outstanding | 206.55M |
| Shares Change (YoY) | +21.12% |
| Shares Change (QoQ) | +0.90% |
| Owned by Insiders (%) | 0.85% |
| Owned by Institutions (%) | 48.53% |
| Float | 79.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 11.73 |
| P/TBV Ratio | 11.75 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.27
| Current Ratio | 7.27 |
| Quick Ratio | 6.82 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -80.10% and return on invested capital (ROIC) is -52.64%.
| Return on Equity (ROE) | -80.10% |
| Return on Assets (ROA) | -46.73% |
| Return on Invested Capital (ROIC) | -52.64% |
| Return on Capital Employed (ROCE) | -76.97% |
| Weighted Average Cost of Capital (WACC) | 8.70% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.71M |
| Employee Count | 315 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -698,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +174.95% in the last 52 weeks. The beta is 0.81, so Immunovant's price volatility has been lower than the market average.
| Beta (5Y) | 0.81 |
| 52-Week Price Change | +174.95% |
| 50-Day Moving Average | 37.77 |
| 200-Day Moving Average | 29.04 |
| Relative Strength Index (RSI) | 64.04 |
| Average Volume (20 Days) | 1,002,958 |
Short Selling Information
The latest short interest is 17.76 million, so 8.60% of the outstanding shares have been sold short.
| Short Interest | 17.76M |
| Short Previous Month | 17.99M |
| Short % of Shares Out | 8.60% |
| Short % of Float | 22.21% |
| Short Ratio (days to cover) | 11.24 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -566.00M |
| Pretax Income | -538.92M |
| Net Income | -538.22M |
| EBITDA | -565.61M |
| EBIT | -566.00M |
| Earnings Per Share (EPS) | -$2.82 |
Balance Sheet
The company has $797.80 million in cash and no debt, with a net cash position of $797.80 million or $3.86 per share.
| Cash & Cash Equivalents | 797.80M |
| Total Debt | n/a |
| Net Cash | 797.80M |
| Net Cash Per Share | $3.86 |
| Equity (Book Value) | 735.39M |
| Book Value Per Share | 3.57 |
| Working Capital | 734.08M |
Cash Flow
In the last 12 months, operating cash flow was -$414.30 million and capital expenditures -$8,000, giving a free cash flow of -$414.31 million.
| Operating Cash Flow | -414.30M |
| Capital Expenditures | -8,000 |
| Depreciation & Amortization | 394,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -414.31M |
| FCF Per Share | -$2.01 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Immunovant does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.12% |
| Shareholder Yield | -21.12% |
| Earnings Yield | -6.23% |
| FCF Yield | -4.80% |
Analyst Forecast
The average price target for Immunovant is $47.88, which is 14.49% higher than the current price. The consensus rating is "Buy".
| Price Target | $47.88 |
| Price Target Difference | 14.49% |
| Analyst Consensus | Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |